These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31050621)

  • 1. Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center.
    Suna N; Özer Etik D; Öcal S; Selçuk H
    Exp Clin Transplant; 2019 Oct; 17(5):632-637. PubMed ID: 31050621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis.
    Herrera I; Pascual S; Zapater P; Carnicer F; Bellot P; María Palazón J
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1194-7. PubMed ID: 27294486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil].
    Freitas AC; Parolin MB; Stadnik L; Coelho JC
    Arq Gastroenterol; 2007; 44(3):189-94. PubMed ID: 18060269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma in Ceará: Epidemiology and Treatment in a Reference Liver Transplant Center in Northeast Brazil.
    Costa PEG; Garcia JHP; Coelho GR; Barros MAP; Hyppolito EB; Pereira KB; Rocha TDDS; Costa GCG
    Transplant Proc; 2024 Jun; 56(5):1083-1086. PubMed ID: 38423832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Characteristics and Long-Term Outcome of Incidental Hepatocellular Carcinoma After Orthotopic Liver Transplant.
    Mourad MM; Algarni A; Aly MA; Gunson BK; Mergental H; Isaac J; Muiesan P; Mirza D; Perera MT; Bramhall SR
    Exp Clin Transplant; 2015 Aug; 13(4):333-8. PubMed ID: 26295183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.
    Freitas AC; Shiguihara RS; Monteiro RT; Pazeto TL; Coelho JC
    Arq Bras Cir Dig; 2016 Mar; 29(1):21-5. PubMed ID: 27120734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods.
    Van Thiel DH; Yong S; Li SD; Kennedy M; Brems J
    Liver Transpl; 2004 May; 10(5):631-7. PubMed ID: 15108254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
    Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
    J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of incidental hepatocellular carcinoma after liver transplant.
    Aktas S; Karakayali H; Moray G; Haberal N; Bilezikci B; Haberal M
    Exp Clin Transplant; 2011 Jun; 9(3):187-90. PubMed ID: 21649567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.
    Nkontchou G; Aout M; Mahmoudi A; Roulot D; Bourcier V; Grando-Lemaire V; Ganne-Carrie N; Trinchet JC; Vicaut E; Beaugrand M
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1007-14. PubMed ID: 22525582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study.
    Du ZQ; Zhao JZ; Dong J; Bi JB; Ren YF; Zhang J; Khalid B; Wu Z; Lv Y; Zhang XF; Wu RQ
    World J Gastroenterol; 2019 Jul; 25(28):3798-3807. PubMed ID: 31391774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
    Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
    Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.
    De Santis A; Iegri C; Kondili L; Riggio O; Salvatori FM; Catalano C; Di Martino M; Bassanelli C; Lupo M; Lucatelli P; Attili AF
    Dig Liver Dis; 2014 Aug; 46(8):726-30. PubMed ID: 24893685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.
    Cucchetti A; Trevisani F; Cescon M; Ercolani G; Farinati F; Poggio PD; Rapaccini G; Nolfo MAD; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Pinna AD;
    J Hepatol; 2012 May; 56(5):1089-1096. PubMed ID: 22245900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.
    Zenouzi R; Weismüller TJ; Hübener P; Schulze K; Bubenheim M; Pannicke N; Weiler-Normann C; Lenzen H; Manns MP; Lohse AW; Schramm C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1733-8. PubMed ID: 24530461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
    Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
    Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.